Breaking Canadian GLP-1 news
GLP-1 News — Page 2
Drug approvals, price changes, generic timelines, and clinical trial results affecting GLP-1 medication costs in Canada.
Find my best option
Answer a few quick questions — get your cheapest path to a GLP-1 prescription, free.
Health Canada Registry: Six Generic Semaglutide Files Pending
Health Canada's public submissions registry shows six generic semaglutide applications still under review after the June 29, 2026 Sevmia authorization.
TrumpRx US GLP-1 Deal: Limited Spillover for Canadian Prices
US TrumpRx program starts GLP-1 prices at US$350 dropping to US$245, but Canadian prices are already lower and generic semaglutide is reshaping the market.
Vimy Pharma Eyes Edmonton-Made Generic Semaglutide Launch
Toronto-based Vimy Pharma plans to file generic semaglutide with Health Canada, with production slated for an Edmonton facility employing about 30 people.
Apotex CEO Says US Launch of Generic Semaglutide Not in 2026
Apotex CEO Martin Arès told the BBC the company's generic semaglutide will not reach the US market in 2026 despite tentative FDA approval.
Sandoz Files US Generic Tirzepatide Applications; Canada Watches
Sandoz files two US generic tirzepatide applications with the FDA, estimating $200-$400 monthly pricing, as Canadian tirzepatide patents differ from US 2036 protection.
Health Canada Approves Sevmia (Apotex): Canada’s First Generic Wegovy
Health Canada approved Sevmia (Apotex) on June 29, 2026 — the first generic version of Wegovy and the first generic semaglutide cleared for weight management in Canada. Pricing has not been published yet.
Pharmacy-Level Generic Semaglutide Switch Mechanics Detailed
Endor Health details how Canadian pharmacies will substitute generic semaglutide at refill, with pCPA tiers setting public-plan prices at 85% down to 35% of brand.
Sandoz Cites Brazil Priority Review as Canada Wait Stretches On
Sandoz Canada points to Brazil's proactive prioritization of generic semaglutide submissions as the Canadian regulator continues to send back questions a year after filing.
Health Canada Review Cites 7.1M GLP-1 Prescriptions in 2023
Health Canada's Summary Safety Review discloses 7.1 million GLP-1 receptor agonist prescriptions dispensed by Canadian retail pharmacies in 2023.
Federal Budget Skips Health Canada Generic Backlog Fix: CGPA
Canada's federal budget omitted new Health Canada resources to clear a generic drug backlog, drawing criticism from CGPA's Jim Keon as semaglutide files queue.
Alberta Blue Cross: GLP-1 Plan Spend Won't Fall Despite Generic
Alberta Blue Cross's 2026 pipeline report says GLP-1 plan spend is unlikely to fall despite a mid-2026 semaglutide generic, citing expanding uses and growing demand.
Novo Nordisk Details SOUL Trial Behind Rybelsus MACE Approval
Novo Nordisk Canada president Vince Lamanna detailed the SOUL trial of 9,650 patients behind Health Canada's MACE indication expansion for Rybelsus tablets.
Seven Generic Semaglutide Files Remain Under Health Canada Review
Health Canada is reviewing seven additional generic semaglutide submissions after Dr. Reddy's and Apotex authorizations, with more decisions expected in coming weeks.
Novo Nordisk Aligns Brand Ozempic Price With Generics in Canada
Novo Nordisk cuts brand-name Ozempic pricing for uninsured Canadians via its Savings Card, aligning costs with newly arrived generics from Apotex and Dr. Reddy's.
Eli Lilly Raises Mounjaro Prices in Canada Amid Trump Pressure
Eli Lilly raised Mounjaro list prices in Canada and Britain after Trump administration pressure, with Kwikpen wholesale prices now ranging $387 to $773.
Health Canada Safety Review: No GLP-1 Suicide Link in T2D Patients
Health Canada's Summary Safety Review found no evidence linking GLP-1 receptor agonists to suicide or self-harm in type 2 diabetes patients; obesity data inconclusive.
Apotex, Dr Reddy's Map Divergent Global Paths for Generic Semaglutide
Apotex CEO Martin Arès says the company is exploring US access routes while Dr Reddy's targets 80+ countries excluding US, UK and Europe.
TrumpRx Starts at US$350, Phases to US$245 as Canada Goes Generic
TrumpRx will sell GLP-1s starting at US$350, dropping to US$245 over two years, while Canada has approved two generic semaglutides, CBC and BMJ report.
Dr. Reddy's Generic Semaglutide Cleared NOD, NON Before Approval
Health Canada's Regulatory Decision Summary reveals Dr. Reddy's generic semaglutide cleared a Notice of Deficiency and Notice of Non-Compliance before April 28 approval.
Novo Nordisk Rebrands: Plosbrio, Poviztra Approved Dec 22, 2025
Health Canada approved two Novo Nordisk rebranded semaglutide products, Plosbrio and Poviztra, on December 22, 2025, as a defensive move against generics.
Looking for current pharmacy prices?
Compare GLP-1 prices across Canada